Trial Profile

A Single-center, Open, Single-arm Clinical Study of the Safety and Efficacy of KD-025 CAR-T Therapy in Advanced NKG2DL+ Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KD 025-Nanjing-KAEDI-Biotech (Primary)
Indications Cholangiocarcinoma; Colorectal cancer; Solid tumours
Focus Adverse reactions; Proof of concept

Most Recent Events

09 Jun 2021 New trial record
02 Jun 2021 According to a Porton Biologics media release, KD-025 CAR-T is being applied for IND at home and abroad.
02 Jun 2021 Results presented in a Porton Biologics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com